Managing Chronic Illness

People who consistently follow their doctor’s instructions when taking medication have roughly half the risk of dying during the same period compared to those who take it intermittently. This figure should be viewed with some caution. Even individuals who take fake pills consistently also have lower mortality rates, which suggests part of the benefit stems from the fact that people who stick to any medication routine tend to be more health-conscious overall. Still, the risks of skipping doses are well documented — especially for blood pressure drugs, anticoagulants, and anti-rejection medications.

Cost

There’s no cost at all; in fact, it saves money on future treatment for complications. Taking the pills each day takes only a few minutes. The real challenge is sticking to the regimen every single day.

Benefit

This finding comes from a meta-analysis that pooled data from 21 separate studies involving 46,847 participants. Compared to those who took medication irregularly, people who followed their prescription exactly had roughly 44% lower risk of dying during the same timeframe. The raw odds ratio was 0.56, with a 95% confidence interval ranging from 0.50 to 0.63; this interval represents the range within which the true value is likely to fall. When only treatments with proven effectiveness were considered, the risk reduction was about 45% (odds ratio 0.55, 95% CI 0.49–0.62).

Note

This is a somewhat controversial figure and one of the numbers in this guide that requires extra caution. In the same meta-analysis, individuals who consistently took placebos also showed a lower mortality rate (odds ratio 0.56, 95% CI 0.43–0.74). This indicates that a significant portion of the benefit is attributable to the “healthy adherer effect” — the tendency of people who stick to any kind of medication routine to generally maintain healthier habits. Nevertheless, the risks associated with discontinuing medication are very real, particularly for blood pressure drugs, anticoagulants, and anti-rejection medications.

Patients with hypertension, diabetes, outpatient radiotherapy/chemotherapy for malignant tumors, dialysis for uremia, and anti-rejection treatment after organ transplants can now use their yibao coverage for outpatient care anywhere in the country. They won’t need to pay out-of-pocket first and then seek reimbursement back home. However, this only works if they first obtain outpatient chronic disease certification in their home region, then register for cross-regional medical care. Both steps are required for it to take effect.

Cost

No cost at all. You can complete the cross-regional medical registration once, right from your phone, via the yibao app before you travel.

Benefit

According to official documents from the National Healthcare Security Administration, this system is now largely in place. The exact wording reads: “Cross-regional direct settlement of outpatient expenses for five chronic conditions — hypertension, diabetes, radiotherapy/chemotherapy for malignant tumors, dialysis for uremia, and anti-rejection treatment after organ transplants — is now largely accessible at the county level.” “Accessible at the county level” means this service is available county-wide. The documents also mention plans to add five more conditions to this list in the future.

Note

Both steps are mandatory: first get outpatient chronic disease certification in your home region, then register for cross-regional medical care. Progress on adding those five new conditions varies by region; exact details are determined by local healthcare security authorities.

For chronic diseases, it’s the trends over time that matter, not any single measurement. Write down the date, the measurement, the medication you’re taking, and its dosage in one place. When you switch doctors, you can show this record so you won’t need to repeat tests or pay for them again.

Cost

Each checkup costs anywhere from a few dozen to several hundred yuan. A trip to the hospital and waiting for results also takes some time. The main difficulty is that you must go regularly, which can easily be put off.

Benefit

What matters for chronic conditions is how these values change over time. Keeping them all in one spot also means you won’t have to redo tests or spend extra money when you change medical providers.

Note

Be sure to record at least four items each time: the date, the measurement value, the medication being used, and its dosage. Taking a photo of the lab report with your phone works just as well. The key is to keep everything in the same place rather than scattering it across multiple notes.

The risks of stopping treatment are well known, while the benefits of folk remedies and supplements are uncertain. This means trading a definite harm for an uncertain gain. If you want to try supplements, talk to your doctor first. Some supplements can alter blood levels of anticoagulants and anti-rejection drugs.

Cost

No cost at all; you even save money you’d otherwise spend on supplements. It takes no extra time. The hard part is resisting repeated pressure from others to give it a try.

Benefit

The dangers of discontinuing treatment are clear, while the advantages of folk remedies remain unproven. This book lists several common types of ineffective supplements in Chapter 6.

Note

Always consult your doctor before trying any supplements. Certain supplements may interact with prescription medications, affecting concentrations of anticoagulants and anti-rejection drugs in the bloodstream.

Individuals whose conditions remain stable and whose medication regimens have not changed can obtain enough medication for 12 weeks from a community health center in one visit. This eliminates the need to travel to a larger hospital each month just to get a prescription and wait in line. Within the same insurance region, reimbursement rates at community-level clinics are typically about 10 percentage points higher than those at higher-tier hospitals.

Cost

There is no cost involved. Simply ask at your local community health center whether they can issue a long-term prescription.

Benefit

Patients no longer need to make monthly trips to larger hospitals just to obtain prescriptions. In the same insurance region, reimbursement rates at community clinics are generally roughly 10 percentage points higher than at higher-tier hospitals.

Note

Whether a patient meets the criteria is determined by the physician; generally, this applies to individuals with a confirmed diagnosis and a stable medication regimen. The actual medication remains the same; what is saved is the time and cost of monthly trips to the hospital and associated fees. If a specific medication is unavailable at a community clinic, patients can inquire about medication shortage registries and delivery services. The same policy also calls for tertiary hospitals to gradually reduce routine outpatient services for such chronic conditions, with those services being transferred to community clinics instead. Relying on larger hospitals solely for prescription refills will become increasingly difficult in the future.

The standard package of basic services is covered by yibao as required. Any customized service packages must be paid for entirely by the patient. When someone offers an “upgrade package,” be sure to ask whether it’s a basic or customized package, whether it’s officially registered, and how much it costs per year.

Cost

There’s no cost involved. Asking a few questions before you sign up takes just a minute.

Benefit

The basic service package is paid for by yibao per regulations. Customized packages require full out‑of‑pocket payment and must also be registered with the county‑level health authority.

Note

The real value of signing up lies in having a doctor follow your health over the long term, not in the number of services included. When offered an “upgrade package,” ask three key questions: is it a basic or customized package, is it registered, and what’s the annual cost?

Diabetes can damage both the retina and feet, but there are almost no noticeable symptoms until the damage becomes severe enough to cause vision loss or foot ulcers. Early detection makes treatment possible. For type 2 diabetes, a dilated eye exam should be done right after diagnosis; for type 1 diabetes, it’s recommended to start five years after onset. If previous tests showed no issues and blood sugar levels remain well-controlled, the interval can be extended to once every one or two years. Foot checks should be done annually.

Cost

A single dilated eye exam costs anywhere from a few dozen to several hundred yuan. Foot exams are usually included in routine outpatient visits, so they don’t incur extra charges. The real challenge is remembering to get these checks done even when neither your eyes nor feet feel any discomfort.

Benefit

Retinal damage caused by diabetes is known as diabetic retinopathy, while damage to the feet is called diabetic foot disease. Both conditions rarely show any symptoms until they reach an advanced stage. Detecting them early gives patients a much better chance of effective treatment. Once vision is lost or foot ulcers develop, it’s usually too late to reverse the damage.

Note

Type 2 diabetics should get a dilated eye exam right after diagnosis; type 1 diabetics should start five years after onset. The difference exists because type 2 diabetes often develops gradually over several years without obvious signs. If previous tests showed no problems and blood sugar stays under control, the interval can be extended to once every one to two years. People who notice reduced sensation in their feet should inspect the soles daily, even using a mirror if needed.

Roughly one in four people who have had a kidney stone will develop another one within five years. In a study of 199 people who had just experienced their first calcium stone episode, one group was instructed to drink enough water every day. Over five years, 12% of this group had a recurrence, compared to 27% of the control group that received no special instructions. UK guidelines recommend drinking 2.5–3 liters of water daily while keeping salt intake under 6 grams.

Cost

There is no cost at all. Simply make drinking water a daily habit. On days when you sweat a lot, you’ll need even more water — the hard part is remembering to do this every day.

Benefit

This is a five-year randomized controlled trial involving 199 patients with idiopathic calcium stones — meaning no underlying cause could be identified. Participants were split into two groups: one group drank at least 2 liters of water daily, while the other received no special intervention. After five years, 12.1% of the water-drinking group had a recurrence, versus 27.0% in the control group (P=0.008). A lower P value indicates a less likely chance that this difference occurred by random chance. The average time to recurrence was 38.7±13.2 months for the water group versus 25.1±16.4 months for the control group (P=0.016). Baseline 24-hour urine volume measurements showed that stone patients produced significantly less urine than healthy individuals: men produced 1,057±238 mL versus 1,401±562 mL in healthy men (P<0.0001), and women produced 990±230 mL versus 1,239±440 mL (P<0.001). NICE guideline NG118, section 1.8.1, offers several recommendations: adults should drink 2.5–3 liters daily, while children and teens should drink 1–2 liters based on age. Adding fresh lemon juice to water is encouraged, and carbonated drinks should be avoided. Adults must also keep daily salt intake under 6 grams.

Note

This measure reduces recurrence rates by roughly 55% at zero cost, making it the most cost-effective recommendation in this section according to our ranking criteria. The key metric to monitor is 24-hour urine volume, which should reach at least 2–2.5 liters — not simply the amount of water you drink. People who sweat heavily or work in hot environments need to drink even more. This trial involved only patients experiencing their first idiopathic calcium stone episode; different types of stones — such as uric acid, infection-related, or cystine stones — require different treatment approaches. Anyone with a history of kidney stones should undergo a stone composition analysis and a 24-hour urine test to determine whether medication is needed. Do not cut calcium intake to prevent stones; see section 6, item 21 for more details. Severe flank or abdominal pain during a stone episode requires immediate medical attention — drinking more water alone will not resolve it. Non-painful blood in the urine may indicate other conditions; see section 1, item 27 for further information. 〔100〕 〔100〕

Gout requires lifelong use of uric‑acid‑lowering drugs to keep levels under 360 µmol/L; painkillers alone are insufficient. In a study where nurses helped patients adjust their dose based on lab results, 95 % reached the target after two years, compared with only 30 % of patients seen by regular doctors. Even after reaching the target, medication must not be stopped. Diet changes alone cannot bring levels down to this point, and abstaining from alcohol lowers them by just 1.6 mg/dL.

Cost

Allopurinol costs only a few to several tens of yuan per month. At first, blood uric‑acid levels must be checked every few weeks to adjust the dose; once stable, checks can be done every few months. For the first 3–6 months, a second medication to prevent flare‑ups is also required. The difficulty lies in the fact that patients must keep taking it even when they feel no pain.

Benefit

In a randomized controlled trial of 517 adults who had experienced gout attacks within the previous 12 months, one group received nurse‑led education and dose adjustments to achieve the target level, while the other continued routine care. After two years, 95 % of the intervention group versus 30 % of the control group had uric‑acid levels below 360 µmol/L (6 mg/dL). The odds of success were 3.18 times higher in the intervention group (RR 3.18, 95 % CI 2.42–4.18; P < 0.0001). Secondary outcomes — attack frequency, tophus formation, and quality of life — also improved. Each additional quality‑adjusted life year gained cost £5,066. Follow‑up data showed that 82 % of participants reported zero attacks in the previous year, versus a median of one attack for the control group (P < 0.001). The proportion still on therapy was 1.19 times higher in the intervention group (adjusted RR 1.19, 1.09–1.30). The 2020 American College of Rheumatology guidelines recommend uric‑acid‑lowering therapy for patients with tophi, bone erosion on imaging, or ≥2 attacks per year; the target is <6 mg/dL, achieved by regular monitoring and dose titration, with allopurinol as first‑line therapy, especially for those with stage 3 or higher chronic kidney disease. Anti‑inflammatory prophylaxis is advised for 3–6 months at initiation. Observational data indicate that after successful control, many patients can discontinue medication without relapse; however, only 13 % remained flare‑free over five years. Alcohol restriction lowers uric‑acid levels by 1.6 mg/dL, while a single beer raises them by 0.16 mg/dL; healthier diets have far smaller effects. Debate persists over optimal drug choice: allopurinol is favored for its efficacy, safety, and low cost, though patients with cardiovascular disease or recent events may be switched to other agents per FDA warnings. The CARES trial linked allopurinol to a 22 % higher risk of all‑cause mortality (HR 1.22) and a 34 % higher risk of cardiovascular death (HR 1.34) versus allopurinol; the European FAST trial found no such increase. Urine alkalinization is not recommended for uricosuric agents due to lack of evidence. Adequate hydration is essential, especially for patients with kidney stones or advanced CKD.

Note

Controversy exists: different countries recommend different first‑line drugs. The U.S. guideline favors allopurinol and advises avoiding febuxostat in patients with cardiovascular disease, whereas the FAST trial found no increased risk with febuxostat. Probenecid, another uricosuric agent, is available in China. Chinese guidelines (2019 and 2024 updates) provide separate recommendations on drug selection and urine alkalinization; they suggest that sodium bicarbonate may be unnecessary, but hydration remains crucial. **Han Chinese individuals should be screened for HLA‑B*5801 before starting allopurinol**; carriers account for 7.4 % of Han Chinese, 0.7 % of Caucasians and Hispanics, and have a three‑fold higher risk of allopurinol‑induced hypersensitivity syndrome, a potentially fatal condition involving extensive skin peeling. The 2020 ACR guidelines recommend screening for these groups. Initiation of therapy can temporarily increase flare‑ups, so anti‑inflammatory prophylaxis for 3–6 months is mandatory; discontinuing uric‑acid‑lowering drugs because of pain is a common cause of treatment failure. When an attack occurs, additional anti‑inflammatory medication should be added per medical advice, not the uric‑acid‑lowering drug. Target levels are expressed as <6 mg/dL (≈360 µmol/L); Chinese labs typically report µmol/L. Asymptomatic hyperuricemia is addressed separately in Section 6, Item 19. Sugar‑sweetened beverages and alcohol are discussed in Section 2, Items 7 and 19.

For individuals with prior gout attacks, consuming high-purine meals over a two-day period raises the odds of an acute recurrent gout attack nearly 5-fold compared to low-purine days, even while taking uric-acid-lowering medications. Consuming two to four alcoholic drinks in the preceding 24 hours raises attack risk by ~50%, across beer, liquor, and wine alike.

Cost

Zero financial outlay. Simply order fewer skewers of meat and seafood dishes, and minimize alcoholic beverages during social dinners. The difficulty is exerting dietary discipline at social dining tables.

Benefit

A 1-year prospective internet-based case-crossover study of 633 gout patients compared dietary intake during the 2-day period preceding an acute gout flare with flare-free control periods in the same individuals. Purines are natural chemical compounds in food metabolized into serum uric acid. Dividing total 2-day purine intake into quintiles revealed that compared with the lowest quintile, the subsequent four quintiles showed odds ratios of recurrent gout attacks of 1.17, 1.38, 2.21, and 4.76 respectively (P for trend < 0.001). For animal purines alone, odds ratios were 1.42, 1.34, 1.77, and 2.41. For plant-derived purines, odds ratios were 1.12, 0.99, 1.32, and 1.39. Subgroup analyses stratified by sex, alcohol consumption, diuretic use, allopurinol therapy, NSAID use, and colchicine prophylaxis yielded consistent findings. A companion study of 724 gout patients evaluated alcohol intake within 24 hours prior to flares: compared with zero alcohol, 1 to 2 drinks increased recurrence risk by 36% (OR 1.36, 95% CI: 1.00–1.88) and 2 to 4 drinks increased risk by 51% (OR 1.51, 95% CI: 1.09–2.09), with risk increasing across wine, beer, and distilled spirits. In incident gout, a 12-year prospective cohort study of 47,150 male health professionals demonstrated that the highest quintile of meat consumption had a 41% higher risk of developing gout than the lowest quintile (RR 1.41, 95% CI: 1.07–1.86), and seafood had a 51% higher risk (RR 1.51, 95% CI: 1.17–1.95), while high dairy consumption reduced risk by 44% (RR 0.56, 95% CI: 0.42–0.74). In the same cohort, each additional 12 oz (355 mL) can of beer per day increased incident gout risk by 49% (RR 1.49, 95% CI: 1.32–1.70), and spirits increased risk by 15% per drink daily (RR 1.15, 95% CI: 1.04–1.28).

Note

Directed primarily at individuals with established gout flares. In individuals without gout, dietary purine intake has a much smaller impact on baseline serum uric acid than commonly believed: in 16,760 white adults without gout, diet explained less than 0.3% of variance in serum urate, whereas common genetic variants explained 23.9%. Thus, while high-purine dining triggers acute attacks, underlying genetic predisposition dominates disease onset. These studies evaluated total purine and ethanol intake rather than cooking technique (cold seafood with beer triggers identical risks to grilled skewers). Dietary restraint cannot replace uric-acid-lowering pharmacotherapy (see Chapter 16, Rule 9). Reducing processed meat and alcohol for cardiovascular mortality is detailed in Chapter 2, Rules 18 and 19.

For individuals carrying chronic hepatitis B virus (HBV), biannual screening with liver ultrasound and alpha-fetoprotein (AFP) reduced liver cancer mortality by nearly 40% in a landmark trial. Higher circulating viral loads directly predict higher lifetime liver cancer incidence. For patients with advanced fibrosis or cirrhosis, starting antiviral therapy cuts liver cancer risk by roughly half. Antiviral treatment is long-term; stopping unilaterally causes severe viral rebound.

Cost

Low cost. Visit hepatology or infectious disease outpatient clinics twice a year for routine blood draws and abdominal sonography; centralized volume-based procurement (VBP) in China has reduced annual generic entecavir antiviral medication expenses to just over 100 RMB. The difficulty is adhering to biannual surveillance and daily long-term oral medication while completely asymptomatic.

Benefit

In a randomized controlled trial in Shanghai involving 18,816 individuals aged 35–59 with chronic HBV infection or history of chronic hepatitis, the screening arm was invited for biannual AFP and ultrasound examinations, while the control arm received routine care without screening. Liver cancer mortality was 83.2 per 100,000 in the screening group vs. 131.5 per 100,000 in the control group, representing a 37% reduction in hepatocellular carcinoma (HCC) mortality (rate ratio 0.63, 95% CI: 0.41–0.98). In the screening group, 46.5% of detected HCC cases underwent curative surgical resections compared to only 7.5% in the control group. In a long-term Taiwanese prospective cohort study (REVEAL-HBV) following 3,653 HBsAg-positive individuals aged 30–65 for a mean of 11.4 years, higher baseline serum HBV DNA levels exhibited a dose-response gradient with HCC incidence: HCC incidence was 108 per 100,000 person-years for viral loads <300 copies/mL vs. 1,152 per 100,000 person-years for >=1,000,000 copies/mL (cumulative HCC incidence of 1.3% vs. 14.9%), persisting after adjustment for age, sex, smoking, alcohol, ALT, and cirrhosis. In an Asian multicenter randomized trial of 651 chronic hepatitis B patients with advanced fibrosis or cirrhosis, lamivudine monotherapy reduced disease progression by 55% (HR 0.45) and HCC incidence by ~50% (3.9% vs. 7.4%, HR 0.49, P = 0.047) over a median of 32.4 months. Chinese Medical Association (CMA) guidelines recommend abdominal ultrasound and AFP screening every 6 months for all chronic HBV carriers, and every 3 to 6 months for high-risk patients. For asymptomatic carriers not meeting treatment criteria, monitor liver panels, viral load, AFP, and ultrasound every 6–12 months. When treatment criteria are met, initiate antiviral therapy immediately; all patients >30 years with detectable HBV DNA are advised to start antivirals regardless of ALT levels, as are patients with family histories of HBV-related cirrhosis or HCC. Modern first-line oral regimens favor high-barrier nucleoside analogues such as entecavir, tenofovir disoproxil fumarate (TDF), or tenofovir alafenamide (TAF).

Note

Controversy: The Cochrane 2003 and 2012 reviews re-analyzed the Shanghai trial using different statistical modeling, concluding that the reduction in HCC mortality did not reach conventional significance (OR 0.81, 95% CI: 0.54–1.22) and citing risk of bias in cluster randomization reporting. Nonetheless, international clinical guidelines uniformly recommend biannual surveillance. Lamivudine was an older agent with a 49% drug resistance mutation rate in trials; modern guidelines recommend entecavir or tenofovir with high genetic barriers to resistance. Treatment initiation and cessation must be determined by a specialist based on viral load, liver biochemistry, fibrosis staging, and family history. Screening uninfected individuals and hepatitis B vaccination are covered in Chapter 1, Rule 14. Hepatitis C antibody screening is covered in Chapter 1, Rule 45. Alcohol-induced liver damage is detailed in Chapter 2, Rule 19.

Only about 30% of inhaler users execute perfect technique; critical errors prevent the aerosol drug from reaching deep airways. Patients making critical errors suffer twice the rate of severe exacerbations and emergency hospitalizations. Furthermore, participating in pulmonary rehabilitation following hospitalization for an acute exacerbation cuts subsequent rehospitalization by more than 50% while improving exercise capacity and quality of life.

Cost

Demonstrating inhaler technique during regular clinical follow-ups incurs zero extra fee beyond regular visits, taking just a few minutes with your device. Supervised pulmonary rehabilitation involves structured exercise sessions, medication coaching, and self-management education across multiple clinical visits, with costs varying by hospital tier. The challenge is persevering with physical training when recovering from a debilitating hospital stay.

Benefit

The China Pulmonary Health (CPH) national survey of 50,991 adults aged >=20 undergoing spirometry showed an overall COPD prevalence of 8.6% (99.9 million individuals), rising to 13.7% among adults aged >=40; only 12.0% of COPD patients had ever received prior spirometry testing. A systematic review of 144 studies evaluating 54,354 patients observed by trained assessors found that only 31% demonstrated correct inhaler technique, 41% showed acceptable technique, and 31% showed poor technique, with zero improvement across two decades. For pressurized metered-dose inhalers (pMDIs), 45% failed to coordinate actuation with inhalation, 44% inhaled too slowly or shallowly, and 46% failed post-inhalation breath-holding. In a real-world French observational study of 2,935 COPD patients, over half made errors; critical device-handling errors that prevent drug delivery occurred in 15.4% to 46.9% across device types. The rate of severe exacerbations requiring hospitalization or ER visits in the preceding 3 months was 3.3% in error-free patients vs. 6.9% in those making critical errors (OR 1.86, 95% CI: 1.14–3.04). The Global Initiative for Chronic Obstructive Lung Disease (GOLD 2023) guidelines mandate educating patients on inhaler mechanics and re-evaluating technique at every follow-up visit. A Cochrane 2016 systematic review of 20 randomized controlled trials (1,477 participants) evaluating pulmonary rehabilitation following an acute COPD exacerbation vs. conventional care found that rehabilitation reduced hospital readmissions by ~56% (OR 0.44, 95% CI: 0.21–0.91; moderate-quality evidence across 8 trials and 810 patients). Six trials evaluating mortality showed OR 0.68 (95% CI: 0.28–1.67; low-quality evidence). Statistically and clinically significant improvements occurred in health-related quality of life and 6-minute walking distance (+62 meters, 95% CI: 38–86; high-quality evidence).

Note

Controversy: Optimal timing of post-exacerbation rehabilitation is debated. A UK trial initiating intensive exercise within 48 hours of acute inpatient admission showed no reduction in 1-year readmissions (HR 1.1) and higher mortality (OR 1.74, 95% CI: 1.05–2.88). GOLD guidance highlights that commencing rehabilitation within 4 weeks of discharge yields clear benefit, but cautioning against aggressive exertion during acute decompensation. For inhalers, specific delivery mechanics vary across Dry Powder Inhalers (DPIs), Soft Mist Inhalers (SMIs), and pMDIs; follow device instruction leaflets and physician demonstrations. Annual influenza vaccination is covered in Chapter 1, Rule 20; pneumococcal vaccination in Chapter 1, Rule 22; smoking cessation pharmacotherapy in Chapter 2, Rule 3.

Only 10% of adults in China with chronic kidney disease (CKD) know they have it. Annual blood and urine testing in patients with diabetes and hypertension detects silent nephropathy years before irreversible kidney failure. For individuals identified with elevated urinary albumin, starting an SGLT2 inhibitor like dapagliflozin reduces composite risk of renal failure, end-stage kidney disease, and renal/cardiovascular death by ~39%, and all-cause mortality by ~31%.

Cost

Low cost. Simply collect a random urine sample for uACR and have blood drawn for serum creatinine (eGFR) during routine clinical follow-ups. The difficulty is remembering to request kidney screening when feeling completely asymptomatic.

Benefit

The 6th China Chronic Disease and Risk Factor Surveillance (176,874 adults undergoing blood and urine testing) revealed an overall CKD prevalence of 8.2% (~82 million adults), with 73.3% residing in early stages 1 and 2; overall awareness of CKD was only 10.0%. A cross-sectional survey across 45 Chinese tertiary hospitals revealed that 31% of 9,672 type 2 diabetes patients had CKD, yet among these 2,997 affected patients, only 27% had ever undergone prior renal screening. The KDIGO 2024 Clinical Practice Guideline mandates testing both urine albumin (uACR) and estimated glomerular filtration rate (eGFR) in at-risk populations, prioritizing individuals with diabetes, hypertension, and cardiovascular disease. The American Diabetes Association (ADA 2026) Standards of Care mandate annual uACR and eGFR screening for all type 2 diabetes patients and type 1 patients with >=5 years' disease duration. In diabetic patients with hypertension and microalbuminuria (uACR 30–299 mg/g), guidelines recommend ACE inhibitors or ARBs. In the landmark DAPA-CKD randomized trial (4,304 CKD patients with eGFR 25–75 and uACR 200–5000), over a median of 2.4 years, the primary composite outcome (>=50% sustained eGFR decline, end-stage kidney disease, or renal/CV death) occurred in 9.2% of the dapagliflozin group vs. 14.5% of placebo (HR 0.61, 95% CI: 0.51–0.72, a 39% relative reduction). All-cause mortality was 4.7% vs. 6.8% (HR 0.69, 95% CI: 0.53–0.88, a 31% relative reduction), with equivalent efficacy regardless of diabetes status.

Note

Graded Evidence Grade B because no randomized trial has compared mortality between "annual screening" vs. "no screening" directly; mortality reductions stem from pharmacological interventions initiated after microalbuminuria is diagnosed. Benefit magnitude is categorized as Moderate. A single elevated uACR does not establish CKD: KDIGO guidelines require repeat confirmation across 2 of 3 specimens within 3 to 6 months. Antihypertensive drug selection must be individualized by physicians. Annual diabetic retinopathy and diabetic foot screening are covered in Chapter 16, Rule 7.

For individuals completing surgery and adjuvant chemotherapy for colon cancer, participating in a 3-year structured, supervised exercise program reduced recurrence, secondary cancers, or death by 28%, and lowered overall mortality by 37%. At 8 years, ~90% of guided exercisers were alive compared to ~83% of those receiving educational materials alone.

Cost

Low cost. Aerobic exercises like brisk walking cost nothing; clinical baseline fitness assessment and exercise prescription at hospital rehabilitation or sports medicine clinics incur outpatient registration fees. Committing several hours weekly over a 3-year structured protocol requires sustained willpower. Exercisers experience slightly higher rates of minor musculoskeletal strains.

Benefit

The multicenter CHALLENGE randomized controlled trial conducted across 55 medical centers enrolled 889 high-risk stage II or stage III colon cancer patients who had completed curative resection and adjuvant chemotherapy without metastasis (enrolled 2–6 months post-chemotherapy, baseline physical activity <150 minutes/week). Participants were randomized to a 3-year structured exercise program (n=445) or health education materials (n=444). The intervention featured bi-weekly behavioral support meetings with physical activity consultants for the first 6 months with supervised exercise, shifting to monthly in-person/phone contacts from months 6–12, and minimal maintenance support through year 3. The goal was adding 10 metabolic equivalent of task (MET)-hours/week of physical activity (achievable via brisk walking). At 1 year, recreational physical activity increased by 15.6 MET-hours/week in the exercise group vs. 5.1 in controls. Over a median follow-up of 7.9 years, disease-free survival (recurrence, new primary cancer, or death) was 28% higher in the exercise group (HR 0.72, 95% CI: 0.55–0.94); 5-year disease-free survival was 80.3% vs. 73.9%. Overall mortality was reduced by 37% (HR 0.63, 95% CI: 0.43–0.94); 8-year overall survival was 90.3% vs. 83.2%. Musculoskeletal adverse events occurred in 18.5% vs. 11.5%. Economic evaluation using Canadian healthcare costs revealed that despite an initial program cost of 2,917 CAD per patient, reduced cancer recurrence resulted in a net 5-year savings of 1,589 CAD per patient.

Note

The CHALLENGE trial strictly enrolled colon cancer patients (excluding rectal cancer) who had undergone complete curative resection and chemotherapy without distant metastases; findings cannot be generalized to advanced metastatic disease or other malignancies. Overall mortality was a secondary endpoint; authors noted findings are consistent with extended survival. Consult oncology and rehabilitation specialists for individualized exercise prescriptions and baseline cardiopulmonary assessments. Daily walking volume benchmarks are covered in Chapter 2, Rule 11. Resistance strength training is detailed in Chapter 2, Rule 16. Beneficiary is yourself.